Citations

Clear

922 citation(s) found for "He, Jun".

Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States
Ahn, Joseph , Lauzon, Marie , Luu, Michael , Noureddin, Mazen , Ayoub, Walid S. , Kuo, Alexander , Sundaram, Vinay , Kosari, Kambiz , Nissen, Nicholas N. , Hendifar, Andrew , Roberts, Lewis R. , Yang, Ju Dong , Ahn, Joseph C , Singal, Amit , Yang, Ju Dong , Roberts, Lewis R , Gong, Jun , Abou‐Alfa, Ghassan K. , Singal, Amit G.

Mayo Clinic

Hepatology | April 16, 2022 | Volume: 76 | Issue: 6 | Pages: 1649-1659

10.1002/hep.32527 | PMID 35429171 Get It

Abstract Background and Aims Immunotherapy has emerged as an effective treatment for patients with advanced‐stage HCC. We aimed to investigate the efficacy of immunotherapy for advanced HCC in a nationwide cohort and racial and ethnic disparities in access to immunotherapy. Approach and Results We used the US National Cancer Database to identify patients with tumor‐node‐metastasis stage 3 or 4 HCC between 2017 and 2018. We performed multivariable Cox regression to identify factors associated with overall survival (OS) and logistic regression to identify factors associated with receipt of immunotherapy. Of the 3,990 patients treated for advanced HCC, 3,248 (81.4%) patients received chemotherapy and 742 (18.6%) patients received immunotherapy as a first‐line treatment. Immunotherapy was associated with improved OS compared with chemotherapy (adjusted HR: 0.76, 95% CI: 0.65–0.88) after adjusting for covariates. There were racial and ethnic disparities in access to immunotherapy, with Hispanic (adjusted OR [aOR]: 0.63, 95% CI: 0.46–0.83) and Black patients (aOR: 0.71, 95% CI: 0.54–0.89) less likely to receive immunotherapy compared with White patients. There was a significant interaction between race‐ethnicity and facility type, with higher disparity observed in nonacademic centers (interaction p = 0.004). Conclusions Immunotherapy was associated with improved OS compared with chemotherapy in advanced HCC. There are significant disparities in early access to immunotherapy, likely due to differential access to clinical trials and experimental therapies. A comprehensive approach to monitoring and eliminating racial‐ethnic disparities in the management of advanced HCC is urgently needed.
Optimal false discovery rate control for large scale multiple testing with auxiliary information
Cao, Hongyuan , Zhang, Xianyang , Chen, Jun

Mayo Clinic

The Annals of Statistics | April 8, 2022 | Volume: 50 | Issue: 2 | Pages: No page available

10.1214/21-aos2128 | PMID 37138896 Get It

MR elastography of liver disease: State of the art
Glaser, Kevin J. , Talwalkar, Jayant A., Chen, Jun , Yin, Meng , Ehman, Richard L.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 5-12

10.37549/ar1982 Get It

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Tang, Yi-Hui , Lin, Guan-Jie, Ma, Yu‐Bin , Desiderio, Jacopo , Li, Ping , Lü, Jun, Cao, Long‐Long, Zheng, Chao‐Hui , Parisi, Amilcare , Truty, Mark J. , Huang, Chang‐Ming , Lin, Jian‐Xian , Xie, Jian‐Wei , Wang, Jia-Bin , Chen, Qi‐Yue , Lin, Mi , Tu, Ru‐Hong

Mayo Clinic

JAMA Network Open | April 1, 2022 | Volume: 5 | Issue: 4 | Pages: e225557

10.1001/jamanetworkopen.2022.5557 | PMID 35363268 Get It

Development of Dilated Esophagus, Sigmoid Esophagus, and Esophageal Diverticulum in Patients With Achalasia: Japan Achalasia Multicenter Study
Sato, Hiroki , Shiwaku, Hironari , Shiota, Junya , Sakae, Hiroyuki , Ominami, Masaki , Hata, Yoshitaka , Fukuda, Hisashi , Ogawa, Ryo , Tatsuta, Tetsuya , Yokomichi, Hiroshi , Terai, Shuji , Inoue, Haruhiro , Fujiyoshi, Yusuke , Abe, Hirofumi , Sato, Chiaki , Nakamura, Jun , Ikebuchi, Yuichiro

Mayo Clinic

Journal of Neurogastroenterology and Motility | April 1, 2022 | Volume: 28 | Issue: 2 | Pages: 222-230

10.5056/jnm21188 | PMID 35362448 Get It

Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes
Lee, Sung Hwan , Yim, Sun Young , Jeong, Yun Seong , Li, Qi‐Xiang, Kang, Sanghee , Sohn, Bo Hwa, Kumar, Shwetha V. , Shin, Ji‐Hyun , Choi, You Rhee, Kim, Hayeon , Kim, Ji Hoon , Kim, Shin , Guo, Sheng , Johnson, Randy L. , Kang, Koo Jeong , Chun, Yun Shin , Jang, Hee Jin, Lee, Byoung Gill, Woo, Hyun Goo , Akbani, Rehan , Roberts, Lewis R. , Wheeler, David A. , Kang, Sang-Hee , Kim, Ji Hoon , Ha, Min Jin , Roberts, Lewis R , Shim, Jae‐Jun , Kaseb, Ahmed O , Lee, Ju‐Seog

Mayo Clinic

Hepatology | March 29, 2022 | Volume: 76 | Issue: 6 | Pages: 1634-1648

10.1002/hep.32490 | PMID 35349735 Get It

Abstract Background and Aims Although many studies revealed transcriptomic subtypes of HCC, concordance of the subtypes are not fully examined. We aim to examine a consensus of transcriptomic subtypes and correlate them with clinical outcomes. Approach and Results By integrating 16 previously established genomic signatures for HCC subtypes, we identified five clinically and molecularly distinct consensus subtypes. STM (STeM) is characterized by high stem cell features, vascular invasion, and poor prognosis. CIN (Chromosomal INstability) has moderate stem cell features, but high genomic instability and low immune activity. IMH (IMmune High) is characterized by high immune activity. BCM (Beta‐Catenin with high Male predominance) is characterized by prominent β‐catenin activation, low miRNA expression, hypomethylation, and high sensitivity to sorafenib. DLP (Differentiated and Low Proliferation) is differentiated with high hepatocyte nuclear factor 4A activity. We also developed and validated a robust predictor of consensus subtype with 100 genes and demonstrated that five subtypes were well conserved in patient‐derived xenograft models and cell lines. By analyzing serum proteomic data from the same patients, we further identified potential serum biomarkers that can stratify patients into subtypes. Conclusions Five HCC subtypes are correlated with genomic phenotypes and clinical outcomes and highly conserved in preclinical models, providing a framework for selecting the most appropriate models for preclinical studies.
Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas
Nelson, Lauren Hassan, Yin, Jun , Asmus, Erik, Ryder, Mabel , Morris, John C. , Hilger, Crystal, Bible, Keith C. , Rao, Sarika , Hassan Nelson, Lauren, Fuentes-Bayne, Harry, Yin, Jun , Hilger, Crystal R, Rao, Sarika N , Ryder, Mabel , Nelson, Lauren Juliette Hassan, Fuentes, Harry E , Morris, John C, Chintakuntlawar, Ashish V.

Mayo Clinic

Journal of the Endocrine Society | March 25, 2022 | Volume: 6 | Issue: 5 | Pages: No page available

10.1210/jendso/bvac044 | PMID 35402763 Get It

Abstract Context Metastatic pheochromocytomas and paragangliomas (mPPGL) are rare vascular neuroendocrine tumors that highly express vascular growth factors. Systemic treatment options in cases of unresectable multisite disease are limited. Multikinase inhibitors that inhibit angiogenesis, such as lenvatinib, have proven effective in several other malignancies, and may be a viable option for mPPGL. Objective We aimed to evaluate the efficacy of lenvatinib as salvage therapy in mPPGLs. Methods This was a retrospective analysis of mPPGL patients ≥ 18 years of age who received lenvatinib from 2015 to 2020 at a tertiary referral center. Patients were started on lenvatinib 20 mg daily and dose was adjusted according to tolerance or disease progression. Results Eleven patients were included. Median treatment duration was 14.7 months (95% CI, 2.3-NE). Treatment was discontinued due to disease progression, adverse events, or death. Overall survival at 12 months was 80.8% (95% CI, 42.3-94.9%) but its median was not reached. Median progression-free survival was 14.7 months (95% CI, 1.7-NE). Among the 8 patients with measurable disease, overall response rate was 63%, as 5/8 experienced a partial response and 3/8 had stable disease. Worsening hypertension and anemia were the most common adverse events. Conclusion Lenvatinib may be a viable treatment option for mPPGL, although at the potential risk of worsening hypertension. Larger, multicenter studies are needed to better characterize treatment efficacy.
Abstract 285: Renal Inflammation and Injury Markers Correlate Directly With Cortical and Fractional Hypoxia Measured With Blood Oxygen Level Dependent (BOLD) MR in Human Atherosclerotic Renal Artery Stenosis
Sa’D, A., Crane, John A., Glockner, James F., McKusick, Michael A., Lerman, Lilach O. , Textor, Stephen C., Herrmann, Sandra M. , Eirin, Alfonso , Tang, Hui Jun

Mayo Clinic

Hypertension | March 20, 2022 | Volume: 62 | Issue: suppl_1 | Pages: No page available

10.1161/hyp.62.suppl_1.a285 Get It

Background: Atherosclerotic renal artery stenosis (ARAS) reduces renal blood flow (RBF) and amplifies regional kidney hypoxia, but their relationship to tissue inflammation and injury markers is poorly understood. We tested the hypothesis that renal injury, reflected by renal vein levels of neutrophil gelatinase associated lipocalin (NGAL) and inflammatory cytokines monocyte chemoattractant protein-1 (MCP-1) would be magnified with severe occlusive vascular disease in humans with ARAS. Methods: Inpatient studies performed in patients with ARAS (n=40, 71.3±11% occlusion by CT angiography) or essential hypertension (EH) (n=30), during fixed Na+ intake and ACE/ARB Rx. Single-kidney cortical and medullary perfusion and RBF were measured using multidetector CT, and glomerular filtration rate (GFR) by iothalamate clearance. Tissue deoxyhemoglobin levels (R2*) and fractional kidney hypoxia (% of axial area with R2*>30/s) were measured by BOLD-MRI at 3T. Results: Single kidney RBF, cortical and medullary perfusion were reduced in the post-stenotic kidney, as was GFR. Renal vein NGAL, MCP-1 and fractional hypoxia were higher in patients with ARAS than EH. NGAL and MCP-1 levels correlated directly with cortical R2* and fractional hypoxia (r = 0.52, P <0 .0001 and r = 0.4, P = 0.0006) and with the degree of artey stenosis (r = 0.37, P = 0.04 and r = 0.35, P = 0.05). GFR correlated inversely with NGAL (r= - 0.5, P <0.0001). Conclusions: Our results demonstrate that elevated renal venous markers of kidney inflammation (MCP-1) and injury (NGAL) in ARAS are correlated with the severity of tissue hypoxia as measured by BOLD MR, suggesting a possible link between kidney inflammation and hypoxia.
Abstract 53: Tumor Necrosis Factor-alpha Enhances Adipogenesis of Adipose Tissue-derived Mesenchymal Stem Cells during Evolution of Obesity
Zhu, Xiangyang , Ma, Shuangtao , Woollard, John R. , Jordan, Kyra L., Lerman, Lilach O. , Eirin, Alfonso , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | March 19, 2022 | Volume: 35 | Issue: suppl_1 | Pages: No page available

10.1161/atvb.35.suppl_1.53 Get It

Background: The expansion of adipose mass requires adipocyte precursor cells that originate from multipotent mesenchymal stem cells (MSC). The inflammatory milieu in obesity often involves high levels of tumor necrosis factor (TNF)-α in adipose tissue, but whether this affects MSC function remains unknown. We tested the hypothesis that microenvironmental changes during the evolution of obesity affect MSC function, which may in turn promote obesity. Methods: Domestic pigs were fed with an adipogenic (n=7) or normal (n=7) diet for 16 weeks. Abdominal adipose tissue biopsies were collected at 8, 12, and 16 weeks for histology and MSC culture. Adipose tissue inflammation and MSC levels were evaluated in situ using immunohistochemistry staining for TNF-α, CD34, and Von Willebrand factor (vWF). The adipogenic propensity of MSC was tested in vitro using appropriate differentiation media, with or without supplementation of TNF-α or anti-TNF-α antibody for 3 weeks. Results: Obese pigs had increased body weight and abdominal fat mass (by CT) compared with lean pigs. TNF-α expression in adipose tissue (Figure 1A) was upregulated in obese pigs at 12 and 16 weeks, accompanied by increased numbers of MSC (CD34 + /vWF - ) at 16 weeks. In vitro, MSC derived from obese adipose tissue at 16weeks showed enhanced adipogenesis, which was abolished by anti-TNF-α treatment. Similarly, in lean MSC TNF-α treatment enhanced adipogenesis (Figure 1B). Conclusion: Obesity-induced adipose tissue inflammation may stimulate MSC differentiation into adipocytes, which further increase the adipose tissue mass. Our results support development of anti-inflammatory strategies for obesity management.
Abstract 45: Characterization of a Novel Integrin Binding Protein that is Essential for αIIbβ3 Outside-in Signaling and Hemostasis
Xiang, Binggang, Zhang, Guoying , Ye, Shaojing , Huang, Cai , Tao, Min , Ruan, Changgeng , Smyth, Susan S. , Li, Zhenyu , Liu, Jun , Whiteheart, Sidney W.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | March 19, 2022 | Volume: 35 | Issue: suppl_1 | Pages: No page available

10.1161/atvb.35.suppl_1.45 Get It

Integrins are heterodimeric (α/β) membrane proteins that play fundamental roles in many biological processes, e.g. cell adhesion and spreading, which are important for platelet function and hemostasis. Integrin function is modulated by bi-directional transmembrane signaling: inside-out and outside-in, which is mediated through the interactions between integrin cytoplasmic tails and intracellular, regulatory proteins. Here, we show that VPS33B, a member of the Sec1/Munc18 (SM) family and component of the Class C core of the CORVET/HOPS sorting complexes, binds directly to the β subunit. Overexpression of VPS33B in CHO cells potentiated α IIb β 3 outside-in signaling but not inside-out signaling. Platelets, from megakaryocyte- and platelet-specific VPS33B conditional knockout mice we generated, had normal morphology yet their spreading on fibrinogen was impaired and they failed to support clot retraction. Platelet aggregation and ATP secretion in response to low-dose thrombin were reduced in the VPS33B knockout mice. α IIb β 3 -mediated endocytosis of fibrinogen was also defective. Tail bleeding times were prolonged in the VPS33B knockout mice. Furthermore, VPS33B acted upstream of the RhoA-ROCK-MLC and Rac1 dependent pathways that leads to clot retraction and cell spreading, respectively. Our work demonstrates that vesicular trafficking complexes are a novel class of modifiers of integrin function and in hemostasis. Our data also provide insights into the molecular mechanism and treatment of ARC syndrome.